Drug Problems, Public Health and Falling Life Expectancy

Drug problems can reduce life expectancy because overdoses and related harms often kill people in early or middle adulthood, removing many potential years of life. In the United States, opioid deaths—frequently involving illegally manufactured fentanyl and sometimes stimulants—were an important part of the country’s earlier stagnation and decline in life expectancy.

The latest figures also provide real grounds for hope. Final US data show that life expectancy rose from 78.4 years in 2023 to 79.0 years in 2024. Drug overdose deaths fell sharply in 2024, and provisional estimates indicate another decline in 2025. However, nearly 70,000 estimated overdose deaths in 2025 still represent a severe public health emergency, not a problem that has been solved. (cdc.gov)

Understanding this connection matters because it changes the question. Instead of asking only why an individual used a drug, public health asks what could have prevented illness or death: safer prescribing, timely treatment, naloxone access, continuity of care, accurate drug-market information and protection from stigma.

What the latest US figures show

In 2024, there were 79,384 recorded US drug overdose deaths. The age-adjusted overdose death rate fell by 26.2% from 2023—the largest annual percentage decline between 2014 and 2024. Death rates involving synthetic opioids other than methadone, including fentanyl, fell by 35.6%, while rates involving cocaine and psychostimulants such as methamphetamine also declined. (cdc.gov)

Provisional CDC estimates for 2025 indicate approximately 69,973 overdose deaths, almost 14% fewer than the provisional estimate for 2024. Estimated opioid-involved deaths decreased from 55,296 to 44,564. These preliminary numbers may change as death investigations and toxicology results are completed. They also use different reporting methods from final annual counts, so provisional and final totals should not be treated as directly interchangeable. (cdc.gov)

The broader mortality picture is improving as well. Provisional data show that the US age-adjusted death rate fell by 4.6% in 2025 and reached its lowest recorded level. A final life-expectancy estimate for 2025 was not yet available as of August 2026, so it would be premature to claim a specific new figure. (cdc.gov)

Encouraging national averages can also hide local and demographic inequalities. In 2024, adults ages 35–44 continued to have the highest overdose death rate among the age groups studied. American Indian and Alaska Native people had the highest rate among the reported racial and ethnic groups, even though rates declined across every group examined. (cdc.gov)

How drug deaths influence life expectancy

Life expectancy is a population estimate based on death rates at different ages. It is not a prediction of how long any particular person will live.

Deaths among younger adults have an especially large effect because each death represents many potential years of life lost. A peer-reviewed analysis estimated that opioid-related deaths reduced US life expectancy by 0.67 years in 2022 compared with a hypothetical situation in which those deaths did not occur. The study estimated 3.1 million years of life lost in that year, averaging approximately 38 years per opioid-related death. (pmc.ncbi.nlm.nih.gov)

This does not mean opioids were the only reason US life expectancy fell. Heart disease, COVID-19, cancer, suicide, alcohol-related illness, unequal healthcare access and other causes also shape national mortality. During the 2014–2017 decline, increasing deaths from unintentional injuries—which include many drug overdoses—made the largest negative contribution identified by the CDC analysis. (cdc.gov)

Drug-related harm can also extend beyond a fatal overdose. Possible consequences include:

• HIV, viral hepatitis and serious bacterial infections associated with unsafe injecting
• Injuries and accidents while impaired
• Cardiovascular complications associated with stimulant use
• Suicide or worsening mental distress
• Interrupted treatment after hospitalization, incarceration or relocation
• Reduced tolerance after abstinence, increasing overdose risk if opioid use resumes
• Harm from combining opioids with alcohol, benzodiazepines or other sedating substances

Deaths may involve more than one substance. In 2022, one analysis found that opioid deaths involving cocaine or psychostimulants accounted for approximately half of opioid-related years of life lost. This is one reason a response focused on a single drug can miss the realities of the current supply. (pmc.ncbi.nlm.nih.gov)

Why this is a public health problem—not a personal failure

A substance use disorder is a health condition involving impaired control and continued use despite harm. It is different from physical dependence or tolerance, although these experiences can overlap. Our guide to drug addiction, dependence and tolerance explains these distinctions in more detail.

Personal decisions matter, but choices are made within an environment. Drug potency, counterfeit pills, treatment cost, housing instability, trauma, isolation, discrimination and gaps in healthcare all influence risk. People cannot reliably make safer choices when they do not know what a product contains or cannot access treatment when they are ready.

Stigma makes the situation worse. Language that defines someone by drug use can discourage disclosure, delay emergency calls and make healthcare encounters less safe. Person-first terms—such as “a person who uses drugs” or “a person with opioid use disorder”—recognize the health issue without reducing someone to it.

Public health responses that can save lives

The strongest response combines prevention, emergency preparedness, treatment and long-term social support. No single intervention will meet every person’s needs.

Evidence-based medical and public health measures

Naloxone distribution: Naloxone can temporarily reverse an opioid overdose when given promptly. WHO recommends making it available to people likely to witness an overdose, including people who use opioids, relatives, friends and community workers. It will not treat a stimulant-only overdose, but an unknown overdose still requires emergency help. (who.int)

Medication for opioid use disorder: Buprenorphine and methadone reduce withdrawal and cravings, while extended-release naltrexone is another option for some people. Medication treatment is associated with lower overdose and overall mortality risk. Detoxification without ongoing medication is not recommended as the only treatment for opioid use disorder because returning to use after tolerance has fallen can increase overdose danger. (cdc.gov)

Continuity of care: Hospitals, emergency departments, correctional facilities and community programs can provide direct referrals and continued medication rather than expecting a person in crisis to navigate a complex system alone. Providing naloxone and arranging follow-up before discharge can reduce gaps at particularly vulnerable times. (cdc.gov)

Comprehensive syringe services: Where permitted, these programs can provide sterile equipment, safe disposal, overdose education, naloxone, infection testing and links to medical care and treatment. They address immediate health risks while respecting that readiness for treatment differs between individuals. (cdc.gov)

Responsive surveillance: Rapid toxicology and mortality data allow communities to identify changes in the drug supply and direct resources toward emerging risks. Provisional figures must be interpreted cautiously, but waiting years for perfect data can also cost lives.

Practical suggestions and personal choices

The following steps may reduce risk, but they are not substitutes for medical treatment or public health investment:

• Keep naloxone accessible and ensure people nearby know where it is.
• Avoid using opioids alone, particularly after a period of abstinence.
• Do not mix opioids with alcohol, benzodiazepines or other sedatives.
• Discuss confidential treatment options with a qualified clinician.
• Build contact with at least one trusted person, peer group or recovery service.
• Use a written emergency and relapse-response plan.

Anyone planning a change can review how to get sober and stay sober and learn how to build the right recovery support system. These resources support planning but do not replace professional assessment.

Do not abruptly stop benzodiazepines after regular use without medical advice. Sudden discontinuation or a rapid reduction can cause serious, potentially life-threatening withdrawal, including seizures. A clinician can assess whether a supervised taper is needed. (fda.gov)

Recognizing and responding to a possible overdose

Possible opioid overdose signs include being unable to wake the person, very slow or absent breathing, choking or gurgling sounds, pinpoint pupils, or gray, blue or unusually pale lips and skin.

Emergency guidance: Give naloxone if available, contact local emergency services immediately, support breathing if trained, place the person on their side when appropriate and remain with them. More than one naloxone administration may be needed, and its effects can wear off before the opioid does. Medical evaluation remains necessary. (cdc.gov)

United States: Call 911. Good Samaritan protections vary by state and do not cover every circumstance.

Outside the United States: Call your country’s emergency number. Naloxone access, legal protections and treatment systems differ substantially, so consult local health authorities or a pharmacist before an emergency occurs.

The international picture

Drug-related mortality is not distributed evenly worldwide. North America has experienced an especially severe synthetic-opioid crisis, while other regions may face greater harm from heroin, tramadol, methamphetamine, cocaine or limited access to controlled medicines and treatment.

WHO reports that effective opioid-dependence treatment and naloxone remain unavailable to many people globally. Some countries allow community or over-the-counter naloxone, while others restrict it to healthcare professionals. Treatment rules for methadone and buprenorphine also vary. (who.int)

Comparisons between countries should therefore account for differences in death certification, toxicology capacity, drug markets and healthcare access. A lower recorded overdose rate may sometimes reflect incomplete data rather than lower risk.

Conclusion

Drug problems contributed significantly to the earlier decline and stagnation in US life expectancy, particularly because so many deaths occurred among working-age adults. The sharp fall in overdose mortality during 2024 and the provisional improvement in 2025 show that this trajectory is not inevitable.

Progress remains fragile. Sustaining it requires evidence-based treatment, naloxone, continuity of care, accurate data and policies that treat people with dignity. Recovery support matters, but the burden cannot rest solely on individuals and families; preventing avoidable deaths is a shared public health responsibility.

Frequently asked questions

Are drug overdoses still lowering US life expectancy?

They remain an important source of premature death, but the national situation is improving. US life expectancy rose in 2024 as overdose mortality fell. Final data are not yet available to calculate life expectancy for 2025.

Why do overdose deaths affect life expectancy so strongly?

Many occur among younger and middle-aged adults. Because life expectancy calculations are sensitive to deaths at younger ages, each such death represents a large number of potential life years lost.

Does the recent decline mean the opioid crisis is over?

No. Provisional data indicate almost 70,000 US overdose deaths in 2025. Local trends vary, and changes in the illegal drug supply could reverse national progress.

What treatments have the best evidence for opioid use disorder?

Buprenorphine and methadone have strong evidence for reducing opioid use and mortality. Extended-release naltrexone may also help some people. Treatment choice requires an individual medical assessment and informed consent.

What should I do if someone may be overdosing?

Give naloxone if available and contact local emergency services immediately. In the United States, call 911. Stay with the person, support breathing if trained and do not assume that waking after naloxone means further medical care is unnecessary.